Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of XKH001 in Healthy Adults
NCT05128409Phase 1Unknown
- Sponsor
- Beijing Kanova Biopharmaceutical
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma and atopic dermatitis (AD) comparing XKH001 with Placebo (2 arms). Primary endpoints: Incidence of adverse events (AEs) up to 8 weeks, Incidence of serious adverse events (SAEs) up to 8 weeks and 8 more. Status: unknown.
02
Drugs
xkh001
03
Conditions
asthmaatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05128409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128409.